case_images: PMC5903101_01
case_images: Optical coherence tomography showing an area with subretinal fluid leakage (a) and fluorescein angiography showing the presence of significant pigment epithelial detachment in the perifoveal capillary network (venous phase) just before starting treatment with ranibizumab (b). No polyps were observed. c Indocyanine green angiography performed 3 months later (after initial loading dose of ranibizumab 0.5 mg) showing 3 hyperfluorescent polyps in the superior papillary area of the right eye.
case_images: cop-0009-0172-g01.jpg
case_images: PMC5903101_01_cop-0009-0172-g01.jpg
case_images: F1
case_images: A new OCT showed an area of subretinal fluid and a PED (Fig. 1a). An ICGA, performed shortly before, confirmed the existence of 3 polypoidal lesions in the superior papillary area of the right eye (Fig. 1b).
case_images: Optical coherence tomography at the follow-up visit 4 weeks after combination therapy with ranibizumab 0.5 mg and photodynamic therapy (right eye).
case_images: cop-0009-0172-g02.jpg
case_images: PMC5903101_01_cop-0009-0172-g02.jpg
case_images: F2
case_images: At a follow-up visit 4 weeks later (December 2015), OCT scans showed no improvement in visual acuity or anatomic benefits (Fig. 2).
case_images: Optical coherence tomography performed 4 weeks after administration of the loading dose of aflibercept followed by half-fluence photodynamic therapy (right eye).
case_images: cop-0009-0172-g03.jpg
case_images: PMC5903101_01_cop-0009-0172-g03.jpg
case_images: F3
case_images: OCT examination 4 weeks later (April 2016) revealed the remission of the anatomic lesions (Fig. 3).